Higher levels of NT-proBNP have emerged as a discriminator, indicating an augmented risk for cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) and microalbuminuria, as evidenced in the Steno-2 study. This evidence concerns the gene NPPB and cardiovascular disorder.